HDAC1 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the LoVo human colorectal adenocarcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the HDAC1 gene, enabling loss-of-function studies of a key class I histone deacetylase. The polyclonal format minimizes clonal artifacts and reflects population-level responses relevant to cancer biology research.
The LoVo cell line, established from a metastatic colorectal adenocarcinoma, is an epithelial model widely used in colorectal cancer studies. These cells retain active Wnt and Notch signaling and exhibit invasive properties, making them suitable for dissecting mechanisms of tumor progression and drug response. LoVo cells provide a clinically relevant background for investigating epigenetic regulators like HDAC1 in solid tumor biology.
HDAC1 removes acetyl groups from histones H3 and H4, promoting chromatin compaction and transcriptional repression. It functions within the SIN3A, NuRD, and CoREST corepressor complexes, interacting with SIN3A, MTA1, MBD3, RCOR1, and HDAC2. Activity is modulated by upstream kinases CK2 and PKA and targets downstream effectors including p53, E2F1, and STAT3. Through these interactions, HDAC1 regulates pathways controlling cell cycle, apoptosis, chromatin remodeling, and signaling via Wnt and Notch, positioning it as a critical node in epigenetic and oncogenic networks.
In LoVo cells, HDAC1 ablation relieves transcriptional repression, leading to hyperacetylation of histones and derepression of genes that promote cell cycle arrest and apoptosis. This polyclonal knockout model thus enables the study of HDAC1-dependent oncogenic maintenance, including effects on chromatin dynamics and signal transduction. The heterogeneous knockout population better mimics the variability found in tumors, offering advantages for translational research and therapeutic testing.
These polyclonal knockout cells are ideal for colorectal cancer epigenetics, HDAC inhibitor screening, gene expression profiling, and apoptosis studies. Standard assays include western blotting for HDAC1 and acetyl-histones, RT-qPCR for target genes, cell viability and flow cytometry assays, and ChIP-qPCR for histone acetylation analysis. This model assists in dissecting HDAC1??s transcriptional regulatory functions and evaluating combinatorial treatment strategies. For further inquiries, please contact Ascent Research.
